Overview

High Doses of Candesartan Cilexetil on the Reduction of Proteinuria

Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effects of high doses of candesartan cilexetil and also to assess which dose (16mg, 64mg, 128mg) is the most optimal for the maximum reduction of proteinuria.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Candesartan
Candesartan cilexetil